UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 176, ~~2021~~2022

Odonate Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38318

82-2493065

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

3 East 28^th Street, 10^th Floor

New York, New York 10016

(332) 206-0935

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:


Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share	ODT	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8 3.01 ~~Other~~Notice ~~Events~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On ~~November~~January 176, ~~2021~~2022, Odonate Therapeutics, Inc. ~~announced~~(the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that itNasdaq ~~will~~believes ~~commence~~that athe ~~share~~Company ~~repurchase~~is ~~plan~~a ~~for~~"public upshell" pursuant to 20Listing ~~million~~Rule ~~shares~~5101, inand ~~order~~that tothe ~~return~~continued ~~capital~~listing toof ~~stockholders~~its securities is no longer warranted. The ~~full~~Company ~~text~~will not appeal this determination. Therefore, the Company expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the ~~press~~opening ~~release~~of ~~announcing~~business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the ~~plan~~U.S. isSecurities ~~attached~~and ~~hereto~~Exchange asCommission ~~Exhibit~~(the 99“SEC”), which will remove the Company’s securities from listing and isregistration ~~incorporated~~on ~~herein~~The byNasdaq ~~reference~~Stock Market. Additionally, the Company intends to file with the SEC a Form 15 requesting the suspension of the Company’s reporting obligations.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99		Press release issued on November 17, 2021
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Odonate Therapeutics, Inc.
Date: November 18, 2021	By:	/s/ Michael Hearne
Date: January 7, 2022	By:	/s/ Michael Hearne
		Michael Hearne
		Chief Financial Officer

Filing Compare · Odonate Therapeutics, Inc.